Double-blind, placebo-controlled, parallel-group, randomized multicentre study to assess the efficacy and safety of LAIS Ragweed Sublingual tablet in patients with allergic rhinoconjunctivitis to ragweed pollen
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Lofarma S.p.A
Most Recent Events
- 10 Mar 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 01 Apr 2015 New trial record